Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Merestinib · 2 trials · 8 indications
Number of participants with DLTs
| Arm | Type | Description |
|---|---|---|
| Merestinib (Part A Dose Level 1) | EXPERIMENTAL | Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met. |
| Merestinib (Part A Dose Level 2) | EXPERIMENTAL | Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met. |
| Merestinib + Cisplatin + Gemcitabine (Part B) | EXPERIMENTAL | Merestinib administered orally with cisplatin and gemcitabine administered intravenously (IV). Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met, but Cisplatin and gemcitabine treatment will be limited to a maximum of 8 cycles. |
| Merestinib Fasted | EXPERIMENTAL | Single dose of merestinib administered in fasted state in one of three periods |
| Merestinib Standard Meal | EXPERIMENTAL | Single dose of merestinib administered with a standard meal in one of three periods |
| Merestinib High-Fat Meal | EXPERIMENTAL | Single dose of merestinib administered with a high-fat meal in one of three periods |
| Name | Type | Description |
|---|---|---|
| Merestinib | DRUG | Administered orally |
| Cisplatin | DRUG | Administered IV |
| Gemcitabine | DRUG | Administered IV |
Inclusion Criteria: * Part A: Histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic (solid tumors or non-Hodgkin's lymphoma). * Part B: Biliary tract carcinoma that is unresectable, recurrent, or metastatic. The participant must not have received prior sys...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Merestinib is an investigational small molecule being studied for use in healthy participants and in patients with advanced or metastatic cancer, including biliary tract carcinoma, cholangiocarcinoma, gall bladder carcinoma, solid tumors, and non-Hodgkin's lymphoma. It is in Phase 1 clinical development and is not approved by the FDA.
Merestinib targets MET, a receptor tyrosine kinase, and acts as an inhibitor of this target. By inhibiting MET, the drug is designed to interfere with signaling pathways that can promote tumor growth and progression in certain cancers.
Merestinib is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and tolerability in humans.
Merestinib is in Phase 1 clinical development. It has completed two Phase 1 trials, one in healthy participants and one in Japanese participants with advanced or metastatic cancer. The drug remains investigational and has not received FDA approval.
Merestinib has completed two Phase 1 clinical trials. The first, NCT02779738, enrolled 24 healthy participants in the United States. The second, NCT03027284, enrolled 19 Japanese participants with advanced or metastatic cancer, including biliary tract carcinoma and solid tumors.
Yes, Merestinib is also known as LY2801653. Both names refer to the same investigational drug, and clinical trial records use the LY2801653 designation. Researchers and investors may encounter either name in publications and trial databases.